Scholars@Duke

PET concerns in bevacizumab treatment.

Publication ,  Journal Article
Goessl, C; Grozdanovic, Z
Published in: Nat Med
June 2004
Published version (DOI) Link to item

Duke Scholars

Christopher G. Willett
Author Christopher G. Willett Radiation Oncology

Published In

Nat Med

DOI

10.1038/nm0604-561a

ISSN

1078-8956

Publication Date

June 2004

Volume

10

Issue

6

Start / End Page

561

Location

United States

Related Subject Headings

  • Tomography, Emission-Computed
  • Immunology
  • Humans
  • Fluorouracil
  • Drug Therapy, Combination
  • Colorectal Neoplasms
  • Bevacizumab
  • Antimetabolites, Antineoplastic
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Goessl, C., & Grozdanovic, Z. (2004). PET concerns in bevacizumab treatment. Nat Med, 10(6), 561. https://doi.org/10.1038/nm0604-561a
Goessl, Carsten, and Zarko Grozdanovic. “PET concerns in bevacizumab treatment.” Nat Med 10, no. 6 (June 2004): 561. https://doi.org/10.1038/nm0604-561a.
Goessl C, Grozdanovic Z. PET concerns in bevacizumab treatment. Nat Med. 2004 Jun;10(6):561.
Goessl, Carsten, and Zarko Grozdanovic. “PET concerns in bevacizumab treatment.” Nat Med, vol. 10, no. 6, June 2004, p. 561. Pubmed, doi:10.1038/nm0604-561a.
Goessl C, Grozdanovic Z. PET concerns in bevacizumab treatment. Nat Med. 2004 Jun;10(6):561.

Published In

Nat Med

DOI

10.1038/nm0604-561a

ISSN

1078-8956

Publication Date

June 2004

Volume

10

Issue

6

Start / End Page

561

Location

United States

Related Subject Headings

  • Tomography, Emission-Computed
  • Immunology
  • Humans
  • Fluorouracil
  • Drug Therapy, Combination
  • Colorectal Neoplasms
  • Bevacizumab
  • Antimetabolites, Antineoplastic
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal